Skip to content

Denis Antoine

Johns Hopkins Medicine

3 papers in the library · 61 citations · publishing 2022-2026

Papers

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Journal of Psychopharmacology June 8, 2023 Natalie Gukasyan, Roland R. Griffiths, David B. Yaden et al. 60 citations

Psilocybin-containing mushrooms produce weaker drug effects in people taking SSRI or SNRI antidepressants, with a 47% probability of weaker-than-expected effects for SSRIs and 55% for SNRIs, compared to 29% for bupropion, a non-serotonergic antidepressant. This dampening effect persists for up to three months after discontinuing the antidepressant, based on retrospective survey data from over 2,000 reports. Removing responses involving fluoxetine, which has a long half-life, did not change the result. The findings suggest that serotonergic antidepressants may reduce psilocybin's effects both during use and for a period after stopping.

Serotonergic antidepressant use is associated with weaker psilocybin effects

October 28, 2022 Natalie Gukasyan, Roland R. Griffiths, David B. Yaden et al. 1 citation preprint

Serotonergic antidepressants, such as SSRIs and SNRIs, weaken psilocybin's effects, while the non-serotonergic antidepressant bupropion has less of a dampening effect. In 595 reports of taking psilocybin with an antidepressant, the probability of weaker than expected effects was 0.48 for SSRIs, 0.56 for SNRIs, and 0.29 for bupropion. After discontinuing a serotonergic antidepressant, reduced psilocybin effects persisted for up to 3 months, with odds of reduced effects not significantly different from the first week until 3–6 months post-discontinuation. The findings suggest that serotonergic antidepressants diminish psilocybin's effects both concurrently and for months after stopping.

Impact of Cannabis Edibles Combined With Alcohol on Driving, Field Sobriety Performance, and Subjective Effects: A Within-Participant Crossover Trial.

JAMA network open May 1, 2026 C Austin Zamarripa, Spencer Lin, Mckenna Klausner et al.

Combining cannabis edibles with alcohol worsens driving impairment more than either substance alone. In a controlled experiment with 25 healthy adults who reported prior co-use, driving performance was significantly impaired under most active drug conditions, including 25 mg THC with alcohol at 0.05% breath alcohol concentration. The legal alcohol intoxication limit of 0.08% may be too high when cannabis has also been consumed. Standard field sobriety tests often failed to detect impairment that was evident in driving measures. The findings suggest a need for better impairment detection and policies that account for co-use.